RxDoctor Payments Data

Sunil Patel, MD

Hematology · Houston, TXNPI 1679666473

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,870 of the $4,946 with a category attached, or 78.3%. 13 manufacturers reported payments, led by Sirtex Medical Inc at 55.5% of the total. Reporting peaked in 2023 at $2,846 and has fallen 95.8% since, to $120 in 2025.

$4,946in general payments, 2019–2025

Across 31 payments — averaging $159.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sirtex Medical Inc$3K
  • Johnson & Johnson$1K
  • Athenex Pharmaceutical Division, LLC$350
  • AstraZeneca$156
  • Bristol Myers Squibb$149
  • Genentech USA, Inc.$131
  • plus $246 from 7 others
$3,568,648in research payments, 2019–2025

Across 147 payments — averaging $24,277 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2.8M
  • AstraZeneca$291K
  • Merck$176K
  • Eli Lilly$167K
  • Genentech, Inc.$138K

What the payments were for

  • Consulting fees$3,87078%
  • Speaking & faculty fees$3507%
  • Food & beverage$66613%
  • Education$601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sirtex Medical Inc2$2,744
Johnson & Johnson1$1,170
Athenex Pharmaceutical Division, LLC2$350
AstraZeneca10$156
Bristol Myers Squibb2$149
Genentech USA, Inc.6$131
Comsort, Inc1$100
Genentech, Inc.2$47
E.r. Squibb & Sons, L.L.C.1$37
Blueprint Medicines Corporation1$20
Daiichi Sankyo Inc.1$18
Gilead1$12
Pfizer1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,946 in reported general payments places this provider in the 60th percentile of 97 hematology providers in Texas.

See all hematology providers in Texas

Medicare billing

Part B allowed, 2024
$21,495
Medicare patients
13
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide59$659,893
RevlimidLenalidomide52$644,208
Abiraterone Acetate140$577,650
ImbruvicaIbrutinib26$424,993
PomalystPomalidomide16$378,759
BrukinsaZanubrutinib16$230,498
TasignaNilotinib Hcl24$229,448
XtandiEnzalutamide16$209,634
TagrissoOsimertinib Mesylate12$204,048
ErleadaApalutamide12$179,238
EliquisApixaban149$103,236
Imatinib Mesylate17$102,091
XareltoRivaroxaban24$28,976
Exemestane15$7,933
Anastrozole127$5,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$149$644,20852 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$37$378,75916 claims
Johnson & JohnsonErleada, Xarelto$1,170$208,21436 claims
AstraZenecaTagrisso$156$204,04812 claims
PfizerEliquis$11$103,236149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 97 hematology providers in Texas.

Other hematology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →